Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Surrozen Inc

SRZN
Current price
10.17 USD -0.08 USD (-0.78%)
Last closed 10.19 USD
ISIN US86889P1093
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 42 413 396 USD
Yield for 12 month +104.83 %
1Y
3Y
5Y
10Y
15Y
SRZN
21.11.2021 - 28.11.2021

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

33 USD

P/E ratio

Dividend Yield

Current Year

+12 500 000 USD

Last Year

+12 500 000 USD

Current Quarter

Last Quarter

+4 146 000 USD

Current Year

-27 230 000 USD

Last Year

+12 500 000 USD

Current Quarter

-386 000 USD

Last Quarter

-392 000 USD

Key Figures SRZN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -35 835 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -43.03 %
PEG Ratio
Return On Equity TTM -174.9 %
Wall Street Target Price 33 USD
Revenue TTM 12 500 000 USD
Book Value 1.89 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -22.49 USD
Diluted Eps TTM -22.49 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics SRZN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History SRZN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 14.12.2023
Dividend Date

Stock Valuation SRZN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM 1.7834
Enterprise Value EBITDA 0.7066
Price Book MRQ 6.9966

Financials SRZN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators SRZN

For 52 weeks

4.5 USD 16.19 USD
50 Day MA 10.02 USD
Shares Short Prior Month 49 635
200 Day MA 10.19 USD
Short Ratio 3.4
Shares Short 44 460
Short Percent 1.87 %